Document text
Principal Investigator: Christian W. Mandl
Organization: TIBA BIOTECH, LLC
Fiscal Year: 2021
Award: $278,957
Funding agency: National Institute of Allergy and Infectious Diseases
Project Summary/Abstract (30 lines)
The proposal is to develop an RNA-based multi-antigen SARS-CoV-2 vaccine, supporting NIAID’s call to develop
a vaccine using emerging antigen design strategies and novel delivery approaches. The SARS-CoV-2 pandemic
is actively threatening public health, world economies, and ways of life. Vaccine candidates are in human trials
now, but long-term solutions will require an adaptable vaccine system that can be universalized broadly to all
members of the coronavirus family. Tiba’s vaccine will be innovative in two respects: 1) The inclusion of all four
structural virion proteins will allow a deeper and potentially broader immune response against coronavirus, as
multiple conserved T cell epitopes will be presented by the vaccine. In addition, the incorporation of structural
proteins besides the Spike (S) protein will allow the formation of immunogenic VLPs in situ. 2) Conventional lipid
nanoparticles (LNPs), which are the mainstay of nucleic acid delivery, require a large proportion of “structural”
lipid, resulting in a relatively low RNA content. Tiba has developed a modified dendrimer delivery molecule that
maximizes RNA mass content, protects RNA from degradation, and enables efficient uptake by cells. This
approach will increase immunogenicity and thus effectiveness of the vaccine. The first Phase 1 Aim is to optimize
candidate payloads comprising M, N, and E mRNA or saRNA. Conventional mRNAs encoding the M, N, and E
proteins will be codon-optimized and lead RNA payloads will then be formulated with Tiba’s modified dendrimer
delivery material. With the M, N, and E payloads generated in both saRNA and mRNA formats, effective
immunogenic doses for each will be determined by injecting six-week-old BALB/c mice with nanoparticles at
different doses. The antigen RNA payloads to proceed for titration into S RNA vaccine candidates will be
selected. The minimum effective dose for each M, N, and E mRNA or saRNA will be roughly estimated using a
regression model. Aim 2 will test the lead candidate payloads along with S in mice. Combination formulations
will be generated wherein different masses of the lead M, N, and E RNAs are titrated into the optimal S mRNA
or saRNA formula to identify a formulation mixture that maximizes M, N, and E cellular immune responses while
not suppressing the S humoral response. Treatment doses will deliver the same mass of S RNA across all
groups, and that optimal mass will be chosen based on the results of dose-finding preliminary studies. Using the
results of the study, two mixtures that confer detectable responses against each virion component while not
suppressing S antibody and T cell responses will be selected as lead candidates. For Aim 3, the lead candidates
will be used in a hamster challenge study. Vaccinations will be performed by i.m. injection in golden Syrian
hamsters. Challenges will be performed using the current best practice. The benchmark of success for this study
is evidence of immune responses against firstly the S component of the vaccine, and concomitant protection
against disease, ideally after a single administration. If successful, further development of lead vaccine
candidates and the path to commercialization will be forthcoming in a Phase 2 SBIR Proposal.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><Aerosols><Agar Gel Electrophoresis><Agarose Gel Electrophoresis><Agarose Gel Fractionation><Animals><Antibodies><Antigens><Assay><Autopsy><B cell growth factor><B-Cell Differentiation Factor-1><B-Cell Growth Factor-1><B-Cell Growth Factor-I><B-Cell Proliferating Factor><B-Cell Stimulating Factor><B-Cell Stimulating Factor-1><B-Cell Stimulation Factor-1><B-Cell Stimulatory Factor-1><BALB C Mouse><BALB/c><BCDF-1><BCGF><BCGF-1><BCSF 1><BSF-1><BSF1><Benchmarking><Best Practice Analysis><Binetrakin><Bioassay><Biologic Assays><Biological Assay><Blood><Blood Reticuloendothelial System><Blood Serum><Body Tissues><Booster Immunization><Brain><Brain Nervous System><COVID crisis><COVID epidemic><COVID pandemic><COVID-19 antigen><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 vaccine><COVID-19 virus><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 public health crisis><COVID19 vaccine><COVID19 virus><Cell Body><Cells><Cessation of life><Characteristics><Clinical><Clinical Treatment Moab><Co-Stimulator><CoV-2><CoV2><Codon><Codon Nucleotides><Collaborations><Control Groups><Coronaviridae><Coronavirus><Costimulator><Cricetinae><DNA><Death><Dendrimers><Dendritic Compounds><Dendrons><Deoxyribonucleic Acid><Detection><Development><Disease><Disorder><Dose><E protein><ELISA><Encephalon><Ensure><Enzyme-Linked Immunosorbent Assay><Epidermal Thymocyte Activating Factor><Evaluation><Family><Fibroblasts><Formulation><Gamma interferon><Generations><Genes><Golden Hamsters><Golden Syrian Hamsters><Hamsters><Hamsters Mammals><Harvest><Histopathology><Human><IFN-Gamma><IFN-g><IFN-γ><IFNG><IFNγ><IL-2><IL-4><IL2 Protein><IL4 Protein><Immune Interferon><Immune response><Immunological response><In Situ><In Vitro><Inbred BALB C Mice><Infection><Injections><Interferon Gamma><Interferon Type II><Interferon-gamma><Interleukin 2><Interleukin 2 Precursor><Interleukin II><Interleukin-2><Interleukin-4><Interleukin-4 Precursor><Interleukine 2><Interleukine 2 Precursor><Interleukine II><Lead><Life><Lipids><Lung><Lung Respiratory System><Lymphocyte Mitogenic Factor><Lymphocyte Stimulatory Factor 1><MCGF-2><Mast Cell Growth Factor-2><Measures><Mesocricetus auratus><Messenger RNA><Mice><Mice Mammals><Mitogenic Factor><Modality><Modeling><Modern Man><Monoclonal Antibodies><Murine><Mus><NIAID><National Institute of Allergy and Infectious Disease><Nature><Non-Polyadenylated RNA><Nucleic Acid Vaccines><Pb element><Peptides><Phase><Production><Proteins><Public Health><Quantitative RTPCR><Quantitative Reverse Transcriptase PCR><RNA><RNA Degradation><RNA Gene Products><RNA vaccine><RNA-based vaccine><Recovery><Replication Unit><Replicon><Reporting><Residual><Residual state><Ribonucleic Acid><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 antigen><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 antigen><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><SBIR><Sampling><Sarna><Secondary Immunization><Serum><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Small Business Innovation Research><Small Business Innovation Research Grant><Spleen><Spleen Reticuloendothelial System><Splenocyte><Sterility><Structural Protein><Structure><Syrian Hamsters><System><T cell growth factor><T cell response><T-Cell Epitopes><T-Cell Growth Factor><T-Cell Growth Factor 2><T-Cell Stimulating Factor><T-Lymphocyte Epitopes><Technology><Testing><Thymocyte Stimulating Factor><Tissues><Titrations><Transcript><Transfection><Universities><Vaccinated><Vaccination><Vaccine Antigen><Vaccines><Validation><Viral><Virion><Virus><Virus Particle><Virus Replication><Wuhan coronavirus><base><booster vaccination><commercialization><corona virus><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019 antigen><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus vaccination><coronavirus vaccine><design><designing><develop a vaccine><development of a vaccine><developmental><hCoV19><heavy metal Pb><heavy metal lead><host response><human disease><immune system response><immunogen><immunogenic><immunogenicity><immunoresponse><innovate><innovation><innovative><lFN-Gamma><lead candidate><light scattering><lipid nanoparticle><mAbs><mRNA><mRNA vaccine><mRNA-based vaccine><member><nCoV2><nano particle><nano particle delivery><nano-sized particle><nanoparticle><nanoparticle delivered><nanoparticle delivery><nanosized particle><necropsy><novel><nucleic acid delivery><nucleic acid-based vaccine><pandemic><pandemic disease><postmortem><pre-clinical><preclinical><prototype><pulmonary><qRTPCR><response><severe acute respiratory syndrome coronavirus 2 antigen><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><sterile><success><uptake><vaccination against coronavirus><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine against coronavirus><vaccine candidate><vaccine development><vaccine effectiveness><vaccine for novel coronavirus><vaccine formulation><vector><viral multiplication><viral replication><virus multiplication>